<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_ETH_Zurich_Proof skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:ETH Zurich/Proof</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="title_container"><SPAN id="title_text"><A href="https://2016.igem.org/Team:ETH_Zurich">PAVLOV'S COLI</A></SPAN></DIV><DIV class="menu_container" id="main_menu"><UL class="menu" id="menu"><LI class="menu_item"><A href="https://2016.igem.org/Team:ETH_Zurich">HOME</A></LI><LI class="menu_item"><A>TEAM</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Collaborations">Collaborations</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Attributions">Attributions</A></LI></UL><LI class="menu_item"><A>PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Design">Design</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Demonstrate">Demonstrate</A></LI><LI class="menu_item"><A>MODELING</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Model">Model</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Sensor_Module">Sensor Module</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Switch_Module">Switch Module</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Detector_Module">Reporter Module</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/NO_Release">NO Release</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Parameters">Parameters</A></LI><LI class="menu_item"><A>LAB</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Experiments">Experiments</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/LabResults">Lab Results</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/InterLab">Interlab Study</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Safety">Safety</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Hardware">Hardware</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Notebook">Notebook</A></LI><LI class="menu_item"><A>PARTS</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Basic_Part">Basic Parts</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Composite_Part">Composite Parts</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Part_Collection">Part Collection</A></LI><LI class="menu_item"><A>HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/Human_Practices">Human Practices</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/HP/Silver">Silver</A></LI><LI><A href="https://2016.igem.org/Team:ETH_Zurich/HP/Gold">Gold</A></LI></DIV><DIV class="content_wrapper" id="main_wrapper"><DIV class="sec page_title"><DIV><H1>PROOF OF CONCEPT</H1></DIV></DIV><DIV class="sec white"><DIV><P>

			Our concept is based on three major devices that can be tested and optimised separately. Once they fulfill all of our strict
			criteria, they would be brought together to demonstrate our work. For an initial proof of concept of our work, we here
			present the three devices we decided suit our needs best.

		</P></DIV></DIV><DIV class="sec light_grey"><DIV><H2>AND GATE</H2><P>

			This part takes nitric oxide (NO) and N-Acyl homoserine lactone (AHL) as its inputs and activates downstream gene expression.
			We were able to construct multiple versions of this AND gate (check out our <A href="https://2016.igem.org/Team:ETH_Zurich/Part_Collection">Part Collection</A>).
			After characterisation we decided on how to optimize it to best fit our purpose: detect the physiological concentration
			ranges of NO and AHL during inflammation.

			</P><P> We have chosen the variant that has shown the best dynamic range, <A href="http://parts.igem.org/Part:BBa_K2116041">BBa_K2116041</A>,
				characterised through GFP expression. We could thus show that our first device is functional and works as expected (Figure
				1). </P><DIV class="image_box full_size"><P><B>Figure 1:</B> Demonstration of AND gate behaviour in presence of NO and AHL. Measured 3 hours after induction. Error
					bars indicate S.D. of 3 technical replicates..

				Our <A href="https://2016.igem.org/Team:ETH_Zurich/Switch_Module">model</A> shows that 4-fold activation would be sufficient
				for activating the next device; our switch.
</P></DIV></DIV></DIV><DIV class="sec white"><DIV><H2>SWITCH</H2><P>

			Our switch consists of a recombinase, that irreversibly switches the reporter construct. Different recombinases were constructed:
			TP901, Bxb1. Here again, we focus on optimisation before assembly of all the parts into a larger circuit. We tested the
			recombinases codon optimised, non-optimized, with different RBSs as well as different degradation tags. Our favourite
			recombinase (codon optimized bxb1, <A href="http://parts.igem.org/Part:BBa_K2116026">BBa_K2116026</A>) exhibits the most
			desired kinetic data (Figure 2). According to our <A href="https://2016.igem.org/Team:ETH_Zurich/Switch_Module">model</A>,
			some parameters of the switch (RBS strength and degradation rate of the integrase) must satisfy a specific ratio in order
			for the switch to work optimally. The kinetics shown in figure 2 show an ideal switching behavior, where steady state
			is reached quickly. Moreover in the 48 hours between transformation and measurements the leakiness of the tet promoter
			(0.05% according to our parameter estimation) was not enough to cause undesired flipping. This suggest that our switch
			can in principle store reliable information even for longer periods.

			</P><DIV class="image_box full_size"><P><B>Figure 2:</B> Demonstration of functionality and ideal flipping kinetics of bxb1 expressed under Ptet promoter. Bxb1
					activation by aTc [ng/ml] and recombination mediated GFP expression. Data acquired using flow cytometry, error bars
					indicate SEM .</P></DIV><P>We conclude, that this switching rate is most desired for the whole construct.</P></DIV></DIV><DIV class="sec light_grey"><DIV><H2>REPORTER</H2><P>


			Our final reporter consists of an AHL-inducible promoter flanked by recombinase specific att-sites. While not flipped, the
			reporter will express red fluorescent protein (mNectarine, <A href="http://parts.igem.org/Part:BBa_K2116016">BBa_K2116016</A>).
			Upon flipping, mNectaring expression is expected to cease and <A href="http://parts.igem.org/Part:BBa_K2116017">GFP</A>			production to ensue. For proof of concept we tested our reporter with a constitutive promoter <A href="http://parts.igem.org/Part:BBa_J23118">BBa_J23118</A>			rather than an AHL-inducible promoter. Different reporter variants were tested in conjunction with our recombinases. We
			found that <A href="http://parts.igem.org/Part:BBa_K2116024">BBa_K2116024</A> is most suitable for our purposes, and works
			with our selected <A href="https://2016.igem.org/Team:ETH_Zurich/Switch_Module">switch module</A>. </P></DIV></DIV><DIV class="sec white"><DIV><H3>PROOF OF CONCEPT SIMULATION</H3><P><B>Figure 3</B> shows the functioning of the full system: Pavlov's Coli is encpsulated in a pill and is ingested by the patient. During transit in the gut the system is exposed to the inflammation marker (NO) and the candidate marker (species-specific AHL). In presence of both markers the promoters of the switch start flipping, storing the association event on the DNA. After recovery of the pill, the system is exposed to the candidate marker (AHL) again and since AHL was associated with an inflammation marker, GFP is expressed again. To learn more about the modelling of our system, see <A href="https://2016.igem.org/Team:ETH_Zurich/Model">MODEL</A>.</P><DIV class="image_box full_size"><P><B>Figure 3:</B> Simulation of the full system. Once NO and AHL are detected at the same time, our memory element start switching. After recovery of the pill, the system is exposed to AHL again and expresses GFP if NO and AHL were detected.</P></DIV></DIV></DIV><DIV class="sec light_grey"><DIV><H2>CONCLUSION</H2><P>


			All three BioBrick devices were tested individually and display the desired function. The simulation of the full system shows
			that our system can work in principle, and the experimental data show that the switch is stable enough to store the detected
			information during the whole transit time through the gut. Thus we argue that the concept of <B>associative learning</B>			with our genetic circuit has been proven. The system will be put together, and its function will be demonstrated under
			simulated real-world conditions (<A href="https://2016.igem.org/Team:ETH_Zurich/Demonstrate">Demonstrate</A>).

		</P></DIV></DIV><DIV class="sec blue"><DIV><H2> Thanks to the sponsors that supported our project: </H2></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>